Revolutionary new treatment regimens for multidrug-resistant tuberculosis
- 1 March 2019
- journal article
- editorial
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 19 (3) , 233-234
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the futureInternational Journal of Infectious Diseases, 2019
- The host microbiome and impact of tuberculosis chemotherapyTuberculosis, 2018
- Towards all-oral and shorter treatment regimens for drug-resistant tuberculosisBulletin of the World Health Organization, 2018
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet, 2018
- Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapiesThe Lancet Infectious Diseases, 2018
- Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysisThe Lancet Respiratory Medicine, 2017
- Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in EuropeAmerican Journal of Respiratory and Critical Care Medicine, 2016